Remus Pharma.

{
  "main_header": {
    "sid": 1003851,
    "name": "Remus Pharma.",
    "stock_name": "Remus Pharma.",
    "full_name": "Remus Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/remus-pharma",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "644.35",
    "chg": -5.65,
    "chgp": "-0.87%",
    "dir": -1,
    "prev_price": "650.00",
    "mcapval": "801.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "REMUS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0O5T01011",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": 3600,
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/remus-pharma-1003851-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Remus Pharma. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-remus-pharma-technically-bullish-or-bearish-3740551",
        "imagepath": "",
        "date": "2025-12-02 09:14:56",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Overview</strong></p>\n<p>As of 1 December 2025, Remus Pharma’s technical trend shifted from outright bearish to mildly bearish. This subtle change signals a tentative easing of downward pressure but stops short of confirming a bullish reversal. The stock’s current price stands at ₹713.45, having risen from the previous close of ₹690.00, indicating some short-term buying interest. However, this remains well below its 52-week high of ₹1,360.00, highlighting significant depreciation over the past year.</p>\n<p><strong>Key Technical Indicators: Mixed Signals</strong></p>\n<p>The Moving Average Convergence Divergence (MACD) on the weekly chart is mildly bullish, suggesting some momentum building in the near term. Conversely, the daily moving averages remain bearish, reflecting persi..."
      },
      {
        "title": "How has been the historical performance of Remus Pharma.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-remus-pharma-3694332",
        "imagepath": "",
        "date": "2025-11-12 23:35:06",
        "description": "Answer:\nThe historical performance of Remus Pharma shows significant growth from the fiscal year ending March 2024 to March 2025.\n\nBreakdown:\nIn the fiscal year ending March 2025, Remus Pharma reported net sales of 620.36 Cr, a substantial increase from 212.94 Cr in March 2024. The total operating income mirrored this growth, reaching 620.36 Cr compared to 212.94 Cr the previous year. Total expenditure also rose to 574.67 Cr from 183.98 Cr, with notable increases in the purchase of finished goods and other expenses. Operating profit (PBDIT) increased to 50.67 Cr from 31.79 Cr, while profit before tax rose to 47.34 Cr from 30.17 Cr. The profit after tax also saw an increase, reaching 38.42 Cr compared to 24.28 Cr in the prior year. The consolidated net profit for March 2025 was 29.07 Cr, up from 20.52 Cr. Earnings per share improved significantly to 24.68 from 17.45, and the book value per share adjusted to ..."
      }
    ],
    "total": 70,
    "sid": "1003851",
    "stock_news_url": "https://www.marketsmojo.com/news/remus-pharmaceuticals-1003851"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Remus Pharmaceuticals Ltd has declared <strong>5%</strong> dividend, ex-date: 14 Nov 25",
          "dt": "2025-11-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Remus Pharmaceuticals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 04 Jul 25",
          "dt": "2025-07-04",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Remus Pharma. technically bullish or bearish?

2025-12-02 09:14:56

Technical Trend Overview

As of 1 December 2025, Remus Pharma’s technical trend shifted from outright bearish to mildly bearish. This subtle change signals a tentative easing of downward pressure but stops short of confirming a bullish reversal. The stock’s current price stands at ₹713.45, having risen from the previous close of ₹690.00, indicating some short-term buying interest. However, this remains well below its 52-week high of ₹1,360.00, highlighting significant depreciation over the past year.

Key Technical Indicators: Mixed Signals

The Moving Average Convergence Divergence (MACD) on the weekly chart is mildly bullish, suggesting some momentum building in the near term. Conversely, the daily moving averages remain bearish, reflecting persi...

Read full news article

How has been the historical performance of Remus Pharma.?

2025-11-12 23:35:06

Answer: The historical performance of Remus Pharma shows significant growth from the fiscal year ending March 2024 to March 2025. Breakdown: In the fiscal year ending March 2025, Remus Pharma reported net sales of 620.36 Cr, a substantial increase from 212.94 Cr in March 2024. The total operating income mirrored this growth, reaching 620.36 Cr compared to 212.94 Cr the previous year. Total expenditure also rose to 574.67 Cr from 183.98 Cr, with notable increases in the purchase of finished goods and other expenses. Operating profit (PBDIT) increased to 50.67 Cr from 31.79 Cr, while profit before tax rose to 47.34 Cr from 30.17 Cr. The profit after tax also saw an increase, reaching 38.42 Cr compared to 24.28 Cr in the prior year. The consolidated net profit for March 2025 was 29.07 Cr, up from 20.52 Cr. Earnings per share improved significantly to 24.68 from 17.45, and the book value per share adjusted to ...

Read full news article

View All News